**Question:** The only thrombolytic agent approved for the treatment of acute ischemic stroke is:

A. Alteplase (tissue plasminogen activator, tPA)
B. Streptokinase
C. Urokinase
D. Heparins

**Core Concept:** Acute ischemic stroke is a medical emergency caused by a rapid blockage of an artery supplying blood to the brain, leading to reduced blood flow and brain cell damage. Thrombolytic agents are medications that dissolve blood clots to restore blood flow and potentially limit brain damage.

**Why the Correct Answer is Right:** Alteplase (tPA) is the only thrombolytic agent approved for acute ischemic stroke treatment due to its specific affinity for plasminogen activation, which breaks down blood clots into non-toxic components. tPA is a recombinant form of human tissue-type plasminogen activator, and its administration within a strict timeframe (4.5 hours) can potentially improve patient outcomes by restoring blood flow and minimizing further brain damage.

**Why Each Wrong Option is Incorrect:**

B. Streptokinase: Streptokinase is a different thrombolytic agent derived from bacteria, which works through a similar mechanism as tPA. However, it has a broader substrate specificity and may cause more bleeding complications due to its non-specificity.

C. Urokinase: Similar to streptokinase, urokinase is another thrombolytic agent with non-specific substrate specificity. It has a higher risk of bleeding and is less effective compared to tPA.

D. Heparins: Heparins are anticoagulants that prevent clot formation but are not specifically designed to dissolve pre-existing clots, making them unsuitable for acute ischemic stroke treatment.

**Clinical Pearl:** The treatment window for thrombolytic agents in acute ischemic stroke is quite narrow, emphasizing the importance of rapid diagnosis and decision-making by healthcare professionals.

Additionally, it is crucial to differentiate acute ischemic stroke from other neurological emergencies like subarachnoid hemorrhage or cerebral venous thrombosis, as thrombolytic agents are not indicated in these conditions. In case of stroke, computed tomography (CT) scan is the initial diagnostic test, followed by magnetic resonance imaging (MRI) if necessary.

**Correct Answer: A. Alteplase (tPA)**

The choice of alteplase (tPA) is based on its specific affinity for plasminogen activation and reduced bleeding risk due to its narrow substrate specificity. However, it must be administered within a strict time frame (4.5 hours) after stroke onset to maximize its effectiveness in restoring blood flow and minimizing secondary brain damage.

**Why Each Wrong Option is Incorrect:**

1. Streptokinase (B) and Urokinase (C) are not specific to plasminogen activation, which increases their bleeding risks and reduces their efficacy in stroke treatment compared to alteplase (A).
2. Heparin (D) is an anticoagulant, not a thrombolytic agent. It works by inhibiting the coagulation cascade, preventing clot formation, but